BiotechTube
Cofactor Genomics

Cofactor Genomics

St. Louis, United States· Est.
cofactorgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $48M

Overview

Cofactor Genomics is a private, commercial-stage diagnostics company leveraging its proprietary ImmunoPrism RNA-Seq platform to build multidimensional predictive biomarkers for immuno-oncology. The company's lead program, the OncoPrism assay, is under investigation in the multi-center PREDAPT trial across 11 solid tumor types to predict immunotherapy response. Cofactor operates a CAP/CLIA laboratory and offers both Research Use Only products and Laboratory Developed Tests (LDTs), aiming to improve clinical trial success and patient treatment decisions through precise immune profiling.

Oncology

Technology Platform

ImmunoPrism RNA-Seq platform for immune profiling from FFPE tissue, using machine learning (Predictive Immune Modeling) to create multidimensional biomarkers from ~40 key genes to predict immunotherapy response.

Funding History

2
Total raised:$48M
Series B$30M
Series A$18M

Opportunities

The significant unmet need for accurate predictors of immunotherapy response creates a large market in immuno-oncology diagnostics.
A successful, pan-cancer predictive platform could partner with multiple pharmaceutical companies and be integrated into standard oncology care pathways.
The shift towards multidimensional biomarkers represents a potential paradigm shift that Cofactor is positioned to lead.

Risk Factors

Clinical validation risk: The company's value depends on the success of the ongoing PREDAPT trial and other studies.
Competitive and adoption risk: The market is crowded, and convincing payers to reimburse and clinicians to adopt a new test is challenging.
Regulatory risk: The landscape for Laboratory Developed Tests (LDTs) is evolving and could impose new requirements.

Competitive Landscape

Cofactor competes in the predictive biomarker space for immuno-oncology against companies using genomics (e.g., Foundation Medicine's TMB, Guardant Health), proteomics, and digital pathology. Its key differentiation is the focus on multidimensional RNA signatures from standard FFPE samples, aiming for better accuracy than single-analyte biomarkers like PD-L1.

More companies in Diagnostics & Precision Medicine →More companies in United States →